NCT00652496

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 249 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension. One of the test formulations was given to one eye and bimatoprost 0.03% given to the fellow eye of each patient

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost 0.01% ophthalmic solution	One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
DRUG	Bimatoprost 0.015% formulation 1 ophthalmic solution	One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
DRUG	Bimatoprost 0.015% formulation 2 ophthalmic solution	One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
DRUG	Bimatoprost 0.02% ophthalmic solution	One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
DRUG	Bimatoprost 0.03% ophthalmic solution	Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs

Timeline

• Start date: 2005-01-01
• Primary completion: 2005-05-01
• Completion: 2005-05-01
• First posted: 2008-04-03
• Last updated: 2008-04-03

Locations

1 site across 1 country: United States